Abstract
p66Shc is shown to negatively regulate the life span in mice through reactive oxygen species (ROS) production. Recent reports, however, revealed that p66Shc protein level is significantly elevated in several human cancer tissues and growth-stimulated carcinoma cells, suggesting a mitogenic and carcinogenic role for p66Shc. In this communication, we demonstrate for the first time that p66Shc mediates androgenic growth signals in androgen-sensitive human prostate cancer cells through mitochondrial ROS production. Growth stimulation of prostate cancer cells with 5α-dihydrotestosterone (DHT) is accompanied by increased p66Shc level and ROS production, which is abolished by antioxidant treatments. However, antioxidant treatments do not affect the transcriptional activity of androgen receptor (AR) as observed by its inability to block DHT-induced prostate-specific antigen expression, an AR-dependent correlate of prostate cancer progression. Elevated expression of p66Shc by cDNA transfection increases the basal cell proliferation and, thus, reduces additional DHT-induced cell proliferation. Furthermore, DHT increases the translocation of p66Shc into mitochondria and its interaction with cytochrome c. Conversely, both redox-negative p66Shc mutant (W134F), which is deficient in cytochrome c interaction, and p66Shc small interfering RNA decrease DHT-induced cell proliferation. These results collectively reveal a novel role for p66Shc–ROS pathway in androgen-induced prostate cancer cell proliferation and, thus, may play a role in early prostate carcinogenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bourdon JC . (2007). p53 and its isoforms in cancer. Br J Cancer 97: 277–282.
Davol PA, Bagdasaryan R, Elfenbein GJ, Maizel AL, Frackelton Jr AR . (2003). Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer. Cancer Res 63: 6772–6783.
Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, Contursi C et al. (2005). Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 122: 221–233.
Grossman SR, Lyle S, Resnick MB, Sabo E, Lis RT, Rosinha E et al. (2007). p66 Shc Tumor Levels Show a Strong Prognostic Correlation with Disease Outcome in Stage IIA Colon Cancer. Clin Cancer Res 13: 5798–5804.
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM et al. (1983). LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809–1818.
Jackson JG, Yoneda T, Clark GM, Yee D . (2000). Elevated levels of p66 Shc are found in breast cancer cell lines and primary tumors with high metastatic potential. Clin Cancer Res 6: 1135–1139.
Khanday FA, Santhanam L, Kasuno K, Yamamori T, Naqvi A, Dericco J . (2006). Sos-mediated activation of rac1 by p66shc. J Cell Biol 172: 817–822.
Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR et al. (2001). SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J Urol 166: 1311–1315.
Kuruma H, Egawa S, Oh-Ishi M, Kodera Y, Satoh M, Chen W et al. (2005). High molecular mass proteome of androgen-independent prostate cancer. Proteomics 5: 1097–1112.
Lee MS, Igawa T, Chen SJ, Van Bemmel D, Lin JS, Lin FF et al. (2004a). p66Shc protein is upregulated by steroid hormones in hormone-sensitive cancer cells and in primary prostate carcinomas. Int J Cancer 108: 672–678.
Lee MS, Igawa T, Lin MF . (2004b). Tyrosine-317 of p52(Shc) mediates androgen-stimulated proliferation signals in human prostate cancer cells. Oncogene 23: 3048–3058.
Lim SD, Sun C, Lambeth JD, Marshall F, Amin M, Chung L et al. (2005). Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate 62: 200–207.
Lin MF, Meng TC, Rao PS, Chang C, Schonthal AH, Lin FF . (1998). Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem 273: 5939–5947.
Lotti LV, Lanfrancone L, Migliaccio E, Zompetta C, Pelicci G, Salcini AE et al. (1996). Shc proteins are localized on endoplasmic reticulum membranes and are redistributed after tyrosine kinase receptor activation. Mol Cell Biol 16: 1946–1954.
Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP et al. (1999). The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 402: 309–313.
Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superti-Furga G et al. (1997). Opposite effects of the p52Shc/p46Shc and p66Shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. EMBO J 16: 706–716.
Meng TC, Lin MF . (1998). Tyrosine phosphorylation of c-ErbB-2 is regulated by the cellular form of prostatic acid phosphatase in human prostate cancer cells. J Biol Chem 273: 22096–22104.
Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM et al. (1997). Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3: 2493–2500.
Nemoto S, Combs CA, French S, Ahn BH, Fergusson MM, Balaban RS et al. (2006). The mammalian longevity-associated gene product p66shc regulates mitochondrial metabolism. J Biol Chem 281: 10555–10560.
Orsini F, Migliaccio E, Moroni M, Contursi C, Raker VA, Piccini D et al. (2004). The life span determinant p66Shc localizes to mitochondria where it associates with mitochondrial heat shock protein 70 and regulates trans-membrane potential. J Biol Chem 279: 25689–25695.
Okada S, Kao AW, Ceresa BP, Blaikie P, Margolis B, Pessin JE . (1997). The 66-kDa Shc isoform is a negative regulator of the epidermal growth factor-stimulated mitogen-activated protein kinase pathway. J Biol Chem 272: 28042–28049.
Pacini S, Pellegrini M, Migliaccio E, Patrussi L, Ulivieri C, Ventura A et al. (2004). p66SHC promotes apoptosis and antagonizes mitogenic signaling in T cells. Mol Cell Biol 24: 1747–1757.
Pandolfi S, Bonafe M, Di Tella L, Tiberi L, Salvioli S, Monti D et al. (2005). p66(Shc) is highly expressed in fibroblasts from centenarians. Mech Ageing Dev 126: 839–844.
Park YJ, Kim TY, Lee SH, Kim H, Kim SW, Shong M et al. (2005). p66Shc expression in proliferating thyroid cells is regulated by thyrotropin receptor signaling. Endocrinol 146: 2473–2480.
Pinton P, Rimessi A, Marchi S, Orsini F, Migliaccio E, Giorgio M et al. (2007). Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science 315: 659–663.
Ravichandran KS . (2001). Signaling via Shc family adapter proteins. Oncogene 20: 6322–6330.
Ripple MO, Henry WF, Rago RP, Wilding G . (1997). Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 89: 40–48.
Stevenson LE, Frackelton Jr AR . (1998). Constitutively tyrosine phosphorylated p52 Shc in breast cancer cells: correlation with ErbB2 and p66 Shc expression. Breast Cancer Res Treat 49: 119–128.
Trinei M, Giorgio M, Cicalese A, Barozzi S, Ventura A, Migliaccio E et al. (2002). A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis. Oncogene 21: 3872–3878.
Ventura A, Maccarana M, Raker VA, Pelicci PG . (2004). A cryptic targeting signal induces isoform-specific localization of p46Shc to mitochondria. J Biol Chem 279: 2299–2306.
Veeramani S, Igawa T, Yuan TC, Lin FF, Lee MS, Lin JS et al. (2005). Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells. Oncogene 24: 7203–7212.
Xie Y, Hung MC . (1996). p66Shc isoform down-regulated and not required for HER-2/neu signaling pathway in human breast cancer cell lines with HER-2/neu overexpression. Biochem Biophys Res Commun 221: 140–145.
Yang CP, Horwitz SB . (2000). Distinct mechanisms of taxol-induced serine phosphorylation of the 66-kDa Shc isoform in A549 and RAW 264.7 cells. Cancer Res 60: 5171–5178.
Acknowledgements
We thank the technical supports from the Flow Cytometry core facility at UNMC and Eppley Cancer Center (P30CA036727). This study was supported in part by the Department of Defense Grants (W81XWH-04-1-0908 and W81XWH-06-1-0070), National Institutes of Health (R01 CA88184) and UNMC Graduate Student Fellowship. We thank Dr Ming-Shyue Lee for the initial study of DHT effect on serine-36 phosphorylation of p66Shc. We also acknowledge Dr Larry W Oberley at University of Iowa College of Medicine (Iowa City, IA, USA) and Dr Parmender P Mehta, University of Nebraska Medical Center (Omaha, NE, USA) for the plasmids Mn-SOD and pECFP-N1, respectively.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Veeramani, S., Yuan, TC., Lin, FF. et al. Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells. Oncogene 27, 5057–5068 (2008). https://doi.org/10.1038/onc.2008.143
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2008.143
Keywords
This article is cited by
-
Relevance of the endoplasmic reticulum-mitochondria axis in cancer diagnosis and therapy
Experimental & Molecular Medicine (2024)
-
p66ShcA functions as a contextual promoter of breast cancer metastasis
Breast Cancer Research (2020)
-
Androgen receptor-induced integrin α6β1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer
Oncogene (2020)
-
High Density Lipoproteins Inhibit Oxidative Stress-Induced Prostate Cancer Cell Proliferation
Scientific Reports (2018)
-
p66Shc as a switch in bringing about contrasting responses in cell growth: implications on cell proliferation and apoptosis
Molecular Cancer (2015)